We propose to synthesize potent, stable and bioavailable opioid peptide analogues designed to be i) antagonists or inverse agonists with high selectivity for mu-, delta- or Kappa-opioid receptors and their subtypes as pharmacological tools and ii) opioid compounds with mixed agonist/antagonist profiles for possible therapeutic applications. To reach these goals, we use an interdisciplinary approach incorporating organic synthesis, peptide chemistry, extensive pharmacological characterization and conformational studies.
Specific Aim 1 is based on our recent discovery that substitution of 3-(2,6-dimethyl-4-hydroxyphenyl)propanoic acid (Dhp) for the N-terminal tyrosine residue in opioid peptides produces antagonists at mu-, delta- or Kappa-receptors. We will synthesize Dhp analogues for Tyr1 replacement in opioid peptides that are capable of engaging in a variety of potential hydrophobic or hydrogen-bonding interactions with receptor moieties, with the expectation of obtaining more potent antagonists or inverse agonists, or compounds with a mixed K agonist/u antagonist profile.
In Specific Aim 2 we will substitute the Dhp analogues developed in Specific Aim 1 for Tyr1 in known selective Kappa-, delta- or mu-agonist opioid peptides to convert them into antagonists or inverse agonists with selectivity for Kappa-, delta- or mu-receptors and their subtypes.
In Specific Aim 3 we will develop potent K opioid antagonists or inverse agonists through structural modification of the cyclic tetrapeptide c[Phe-D-Pro-Phe-(D,L)-Trp] (CJ-15,208) recently isolated from the fungus Ctenomyces serratus.
In Specific Aim 4 we will identify opioid peptide analogues containing certain Dhp analogues developed under Specific Aim 1 that have a mixed K agonist/mu antagonist profile as potential agents for the treatment of cocaine abuse.
Specific Aim 5 concerns the development of chimeric opioid peptides with a mixed mu agonist/delta antagonist profile as analgesics with a low propensity to produce tolerance and dependence. The in vitro opioid activity profiles will be determined by performing opioid receptor binding assays, the guinea pig ileum and mouse vas deferens assays, and the [35S]GTPgammaS binding assay. The characterization of some of the compounds in vivo will include determination of the effects on cocaine discrimination and self-administration for the K agonist/mu antagonists and analgesic testing, including tolerance and dependence development, for the mixed mu agonist/delta antagonists. The conformation(s) of select compounds will be examined by 1HNMRspectroscopy in conjunction with theoretical conformational analyses.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004443-22
Application #
7665367
Study Section
Special Emphasis Panel (ZRG1-MDCN-C (95))
Program Officer
Rapaka, Rao
Project Start
1987-06-01
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2011-07-31
Support Year
22
Fiscal Year
2009
Total Cost
$175,621
Indirect Cost
Name
Clinical Research Institute of Montreal
Department
Type
DUNS #
201373169
City
Montreal
State
QC
Country
Canada
Zip Code
H2 1-R7
Willemse, Tom; Eiselt, Emilie; Hollanders, Karlijn et al. (2018) Chemical space screening around Phe3 in opioid peptides: Modulating µ versus ? agonism by Suzuki-Miyaura cross-couplings. Bioorg Med Chem Lett 28:2320-2323
Stoeber, Miriam; Jullié, Damien; Lobingier, Braden T et al. (2018) A Genetically Encoded Biosensor Reveals Location Bias of Opioid Drug Action. Neuron 98:963-976.e5
Toyama, Satoshi; Shimoyama, Naohito; Szeto, Hazel H et al. (2018) Protective Effect of a Mitochondria-Targeted Peptide against the Development of Chemotherapy-Induced Peripheral Neuropathy in Mice. ACS Chem Neurosci 9:1566-1571
Van der Poorten, Olivier; Van Den Hauwe, Robin; Eiselt, Emilie et al. (2017) ?-Space Screening of Dermorphin-Based Tetrapeptides through Use of Constrained Arylazepinone and Quinolinone Scaffolds. ACS Med Chem Lett 8:1177-1182
Starnowska, Joanna; Costante, Roberto; Guillemyn, Karel et al. (2017) Analgesic Properties of Opioid/NK1 Multitarget Ligands with Distinct in Vitro Profiles in Naive and Chronic Constriction Injury Mice. ACS Chem Neurosci 8:2315-2324
Tan, Paul; Blais, Carolane; Nguyen, Thi M-D et al. (2016) Prorenin/renin receptor blockade promotes a healthy fat distribution in obese mice. Obesity (Silver Spring) 24:1946-54
Cai, Yunxin; Lu, Dandan; Chen, Zhen et al. (2016) [Dmt(1)]DALDA analogues modified with tyrosine analogues at position 1. Bioorg Med Chem Lett 26:3629-31
Weltrowska, Grazyna; Nguyen, Thi M-D; Chung, Nga N et al. (2016) A Cyclic Tetrapeptide (""Cyclodal"") and Its Mirror-Image Isomer Are Both High-Affinity ? Opioid Receptor Antagonists. J Med Chem 59:9243-9254
Guillemyn, Karel; Starnowska, Joanna; Lagard, Camille et al. (2016) Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain. J Med Chem 59:3777-92
Gendron, Louis; Cahill, Catherine M; von Zastrow, Mark et al. (2016) Molecular Pharmacology of ?-Opioid Receptors. Pharmacol Rev 68:631-700

Showing the most recent 10 out of 103 publications